Fig. 7From: Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patientsClinical model interpretation using SHAP. The summary plots show each clinical data impact on longitudinal RF model for endpoint PFS6 (a) and endpoint PFS9 (b). A positive SHAP value indicates an increased risk of progression. Each point in the summary plot represents a patientBack to article page